PTGS2 and cancer: Regarding COX-2 intensity of labelling (Table 6), 11/77 (14.3%) tumors presented a strong intensity, corresponding to 8/38 (21%) malignant tumors and 3/39 (7.7%) benign tumors; 15/77 (19.5%) presented a moderate intensity, corresponding to 10/38 (26.3%) malignant tumors and 5/39 (12.8%) benign tumors; 18/77 (23.4%) presented a weak intensity, corresponding to 15/38 (39.5%) malignant tumors and 3/39 (7.7%) benign tumors.